BridgeMD
Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid in renal recipients at high risk of post-transplant cytomegalovirus.
EU CTIS ID: 2025-520854-12-00
What this study is testing
The primary objective of the study is to assess the time from hospital arrival to revascularization in patients with acute ischemic stroke treated with mechanical thrombectomy, depending on whether the procedure was performed under sedation with HFNC or under general anesthesia. Monitor CMV-specific cellular immune response before transplantation and at 15, 30 and 90 days post-transplantation in each of the two treatment groups using Quantiferon-CMV.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age more than or equal 18 years.
- Positive pretransplant Ig G CMV serology
- Receive immunosuppressive induction treatment with thymoglobulin (between 1 and 5 doses).
- - Agree to participate in the study by signing the informed consent form.
You likely can't join if
- Patients with negative pretransplant Ig G CMV serology
- Patients infected with HIV.
- Patients receiving induction therapy with basiliximab
- Patients who cannot comply with the follow-up protocol.
- Patients who cannot receive iMTOR as initial maintenance immunosuppressive therapy, such as patients with chronic kidney disease secondary to hepatorenal polycystic kidney disease and those patients who are expected to undergo complex vascular surgery.
- Patients who for any reason should not be included in the study according to the evaluation of the research team.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.